The highest THC levels in medical marijuana flower typically top out around 30 to 35% in dispensary products, though concentrates like wax, shatter, and hash oil range from 60 to 90%. Pure THC crystalline isolate can reach close to 100%. But those label numbers deserve scrutiny, because independent testing shows that actual THC content is often significantly lower than what’s printed on the package.
THC Levels Across Product Types
Most flower sold in dispensaries falls between 17 and 28% THC, with the average sitting around 21% as of 2022 according to Washington State market data. Some strains are marketed at 30% or higher, but these represent the upper edge of what cannabis flower can realistically produce. The plant’s biology limits how much THC its resin glands can pack into a given amount of dried material.
Concentrates push well past those numbers. Wax, rosin, shatter, and hash oil generally land between 60 and 90% THC. Hash and kief tend to be lower, often in the 30 to 60% range. Distillates, which undergo further refinement, can exceed 90%. At the extreme end, THC crystalline isolate is nearly pure THC, approaching 99%.
Then there are specialty products like moon rocks, which combine flower coated in cannabis oil and rolled in kief. These typically hover around 50% THC, bridging the gap between regular flower and full concentrates.
How THC Potency Has Changed Over Time
Cannabis is dramatically stronger than it was a generation ago. Data from the National Institute on Drug Abuse tracking samples seized by the DEA shows that in 1995, the average THC content was just 3.96%. By 2022, it had climbed to 16.14%. That’s roughly a fourfold increase in average potency over less than three decades, driven by selective breeding focused on maximizing THC production.
This trend has reshaped what patients encounter at dispensaries. A “low potency” product today would have been considered exceptionally strong in the 1990s.
Label Numbers Are Often Inflated
If you’ve seen flower labeled at 30% or higher and wondered whether to take it at face value, the skepticism is warranted. A study published in PubMed Central that independently tested retail cannabis found the actual THC potency was, on average, 23% lower than the lowest number printed on the label, and 36% lower than the highest label value. About 70% of samples tested more than 15% below their labeled THC. Three samples contained only half the THC their labels claimed.
The reasons are straightforward: there are no standardized testing protocols across labs, regulatory oversight is limited, and dispensaries have a financial incentive to stock products with impressive numbers on the label. “Lab shopping,” where producers send samples to whichever lab returns the highest results, has been a known practice in the industry for years. So when you see a strain advertised at 35% THC, the real figure may be closer to 25%.
Higher THC Doesn’t Always Mean Better Relief
One of the most common assumptions in medical marijuana is that stronger means more effective. The research tells a more complicated story. A systematic review of high-potency cannabis studies found inconsistent results when comparing high-THC products to lower-potency options for pain, headaches, and anxiety.
For general pain, higher-potency cannabis did show greater symptom reduction compared to low-potency products. But for migraines specifically, there was no meaningful difference. The anxiety findings were particularly interesting: both mid-potency and high-potency cannabis reduced anxiety symptoms compared to low-potency products, but there was no dose dependence. In other words, the mid-range worked just as well as the strongest option.
This pattern suggests a ceiling effect for many conditions. Beyond a certain threshold, more THC doesn’t translate into more relief.
The Terpene Tradeoff
Breeding cannabis for maximum THC has come at a cost. Terpene levels, the aromatic compounds that contribute to flavor and may influence therapeutic effects, have been declining across the cannabis market over the past decade. Research comparing sun-grown and indoor cannabis found that indoor cultivation, which dominates commercial production, produces flowers with fewer terpenes in both quantity and variety.
This matters because of what’s known as the entourage effect: the idea that cannabinoids and terpenes work together synergistically, producing different therapeutic outcomes depending on their ratios. Terpenes also serve as natural antioxidants in the plant, and when they’re present in lower amounts, cannabinoids degrade and oxidize more readily. A flower with 28% THC but a stripped-down terpene profile may produce a less nuanced or less therapeutic experience than a 20% THC flower with a rich mix of terpenes.
No States Cap THC Potency
If you’re wondering whether your state limits how strong medical marijuana can be, the answer is almost certainly no. States generally do not impose potency caps on cannabis products. They regulate how much product you can purchase by weight, but since those weight limits don’t account for THC concentration, patients can effectively increase their total THC intake by choosing the highest-potency options available.
This regulatory gap means the market is largely self-governing on potency. Dispensaries stock what sells, and what sells tends to be whatever has the highest THC number on the label, which circles back to the inflation problem. The result is a market where perceived potency often matters more than actual potency, and where the products with the most impressive labels aren’t necessarily the ones that deliver the best therapeutic results.